First Trust Advisors LP Theravance Biopharma, Inc. Transaction History

First Trust Advisors LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$14.52 - $22.46 $443,789 - $686,467	-30,564 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$16.57 - $21.08 $506,445 - $644,289	30,564 New	30,564 $624,000
Q4 2020 Feb 02, 2021	SELL	$14.89 - $20.16 $649,323 - $879,137	-43,608 Closed	0 $0
Q3 2020 Nov 05, 2020	SELL	$14.79 - $22.49 $502,519 - $764,142	-33,977 Reduced 43.79%	43,608 $645,000
Q2 2020 Jul 22, 2020	SELL	$20.64 - $30.69 $244,191 - $363,093	-11,831 Reduced 13.23%	77,585 $1.63 Million
Q1 2020 May 06, 2020	BUY	$17.84 - $31.21 $690,836 - $1.21 Million	38,724 Added 76.39%	89,416 $2.07 Million
Q4 2019 Feb 03, 2020	BUY	$16.12 - $25.89 $817,155 - $1.31 Million	50,692 New	50,692 $1.31 Million
Q2 2019 Jul 30, 2019	SELL	$15.6 - $25.15 $1.3 Million - $2.09 Million	-83,039 Closed	0 $0
Q1 2019 May 09, 2019	SELL	$22.57 - $28.15 $103,686 - $129,321	-4,594 Reduced 5.24%	83,039 $1.88 Million
Q4 2018 Feb 07, 2019	BUY	$22.52 - $35.07 $1.97 Million - $3.07 Million	87,633 New	87,633 $2.24 Million
Q4 2017 Feb 08, 2018	SELL	$25.82 - $35.66 $545,266 - $753,067	-21,118 Closed	0 $0
Q3 2017 Oct 24, 2017	BUY	$23.88 - $34.96 $504,297 - $738,285	21,118	21,118 $723,000

122

47.3M

200

12.8K

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $640M
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

Stay updated on First Trust Advisors LP with notifications on news.